INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $261,000 | -44.1% | 3,926 | -33.1% | 0.47% | -31.7% |
| Q2 2019 | $467,000 | -27.5% | 5,872 | +2.0% | 0.69% | -20.8% |
| Q1 2019 | $644,000 | +80.9% | 5,756 | +62.9% | 0.87% | +11.4% |
| Q4 2018 | $356,000 | -29.5% | 3,534 | -11.6% | 0.78% | -35.0% |
| Q3 2018 | $505,000 | +50.7% | 3,998 | 0.0% | 1.21% | +65.9% |
| Q2 2018 | $335,000 | +20.9% | 3,998 | -11.1% | 0.73% | +33.9% |
| Q1 2018 | $277,000 | +25.3% | 4,496 | +19.0% | 0.54% | +184.3% |
| Q4 2017 | $221,000 | -15.0% | 3,779 | -15.7% | 0.19% | -18.0% |
| Q3 2017 | $260,000 | +18.2% | 4,481 | +146.2% | 0.23% | +15.3% |
| Q2 2017 | $220,000 | -41.3% | 1,820 | -45.0% | 0.20% | -27.3% |
| Q1 2017 | $375,000 | +61.6% | 3,312 | +55.1% | 0.28% | +50.3% |
| Q4 2016 | $232,000 | +7.9% | 2,135 | +63.5% | 0.18% | +52.9% |
| Q3 2016 | $215,000 | – | 1,306 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |